FDA Approves Breast Cancer Drug Avastin Despite Opposition by Advisory Panel

Tweet Pin It

(NaturalNews) In a surprise move, the FDA has disregarded the recommendation of its expert advisory panel and approved Genentech's drug Avastin as a breast cancer treatment.

The FDA almost never goes against the recommendations of its advisory panels.

Avastin was approved by the FDA in 2004 for use as a lung and colorectal cancer treatment. The drug blocks the growth of blood vessels in tumors, thus slowing tumor growth. Since 2004, it has frequently been used off-label as a breast cancer treatment, and was approved for that use in Europe even before the recent FDA decision.

In spite of this record, an FDA advisory panel voted 5-4 against approving the drug for breast cancer. While studies have shown that Avastin shrinks breast tumors, there is no evidence that it lengthens or improves the quality of patients' lives.

In a nod to the panel's concerns, the FDA approved Avastin as a breast cancer treatment only conditionally. Avastin may only be used for the most advanced (metastatic) stage of breast cancer, and the FDA may withdraw approval if Genentech does not provide new evidence that the drug is effective.

The FDA placed similar restrictions on the lung cancer drug Iressa several years ago. After more studies failed to demonstrate any benefit from the drug, the FDA asked Iressa maker AstraZeneca to remove it from the market, and the company complied.

Conditional or not, the approval of Avastin has led to speculation that the FDA may be taking a more permissive approach on approving cancer drugs, and has raised the hopes of pharmaceutical company Denedron for its prostate cancer drug Provenge.

In 2007, the FDA denied approval to Provenge, even though the advisory panel had voted 17-0 that it was safe and 13-4 that it was effective. But the FDA was concerned that the apparent benefits from the drug might have been a fluke caused by the small study size, and decided to hold out for more information.

	Stay informed! FREE subscription to the Health Ranger's email newsletter Get breaking news alerts on GMOs, fluoride, superfoods, natural cures and more...
	Join over four million monthly readers. Email privacy 100% protected. Unsubscribe at any time.

Articles Related to This Article: • FDA Running Extortion Racket: Natural Supplement Companies Threatened with Arrest if They Don't Pay Up • The FDA Exposed: An Interview With Dr. David Graham, the Vioxx Whistleblower • Mercury Fillings Shattered! FDA, ADA Conspiracy to Poison Children with Toxic Mercury Fillings Exposed in Groundbreaking Lawsuit • Ending the Atrocities of the FDA; Life Extension Urges Immediate Petition Action for Health Freedom • Murder in the medical Matrix: the FDA • NaturalNews exclusive: FDA wages secret war on raw milk farmers using KGB-style spying and infiltration techniques

Related video from NaturalNews.TV Your NaturalNews.TV video could be here. Upload your own videos at NaturalNews.TV (FREE)

Have comments on this article? Post them here:

 people have commented on this article.

Related Articles: • FDA Running Extortion Racket: Natural Supplement Companies Threatened with Arrest if They Don't Pay Up • The FDA Exposed: An Interview With Dr. David Graham, the Vioxx Whistleblower • Mercury Fillings Shattered! FDA, ADA Conspiracy to Poison Children with Toxic Mercury Fillings Exposed in Groundbreaking Lawsuit • Ending the Atrocities of the FDA; Life Extension Urges Immediate Petition Action for Health Freedom • Murder in the medical Matrix: the FDA • NaturalNews exclusive: FDA wages secret war on raw milk farmers using KGB-style spying and infiltration techniques

Take Action: Support NaturalNews.com Email this article to a friend Permalink to this article: http://www.naturalnews.com/024106_FDA_drug_cancer.html Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. Embed article link: (copy HTML code below): <a href = "http://www.naturalnews.com/024106_FDA_drug_cancer.html">FDA Approves Breast Cancer Drug Avastin Despite Opposition by Advisory Panel</a>